Balyasny Asset Management
OBIO icon

Balyasny Asset Management’s Orchestra BioMed OBIO Stock Holding History

Balyasny Asset Management’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-18,268
Closed -$75.8K – 3334
2025
Q4 		$75.8K Buy
+18,268
New +$73.7K ﹤0.01% 2985

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Balyasny Asset Management's OBIO Position: Q1 2026 in Review

Balyasny Asset Management sold out of Orchestra BioMed (OBIO) in Q1 2026, closing a stake of 18,268 shares — an estimated $75.8K sold.

Balyasny Asset Management first reported a position in OBIO in Q4 2025 and held it in 1 quarter. The position peaked at $75.8K in Q4 2025. 65 funds tracked by Wall St. Rank hold OBIO as of Q1 2026.

  • Balyasny Asset Management reported no remaining Orchestra BioMed position as of Q1 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 18,268 Orchestra BioMed shares in Q1 2026, an estimated $75.8K.
  • Balyasny Asset Management first reported a position in Orchestra BioMed in Q4 2025 and held it in 1 quarter.
  • Balyasny Asset Management's Orchestra BioMed position peaked at $75.8K in Q4 2025.
  • 65 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.